Table: Towa Pharmaceutical - 9-MTH group results
Feb 13 (Reuters)-
Towa Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2017 Dec 31, 2016 Mar 31, 2018
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 70.41 63.70 94.00
(+10.5 pct) (+4.0 pct) (+10.7 pct)
Operating 9.21 5.51 11.80
(+67.2 pct) (-38.3 pct) (+71.8 pct)
Recurring 10.47 6.50 12.00
(+61.2 pct) (-27.2 pct) (+61.8 pct)
Net 7.37 4.80 8.40
(+53.5 pct) (-23.8 pct) (+50.6 pct)
EPS 449.52 yen 292.92 yen 512.10 yen
EPS Diluted 415.74 yen 270.80 yen
Ann Div 95.00 yen 95.00 yen
-Q2 div 47.50 yen 47.50 yen
-Q4 div 47.50 yen 47.50 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results